Pirfenidone's long trudge to FDA approval: InterMune launches new trial (ASCEND-3)
www.pulmccm.org
Unimpressed by the unimpressive results of the CAPACITY trials testing pirfenidone for idiopathic pulmonary fibrosis, the FDA bucked its advisory panel (which had recommended approval) and insisted on another randomized trial in order to reconsider the drug.
Pirfenidone's long trudge to FDA approval: InterMune launches new trial (ASCEND-3)
Pirfenidone's long trudge to FDA approval…
Pirfenidone's long trudge to FDA approval: InterMune launches new trial (ASCEND-3)
Unimpressed by the unimpressive results of the CAPACITY trials testing pirfenidone for idiopathic pulmonary fibrosis, the FDA bucked its advisory panel (which had recommended approval) and insisted on another randomized trial in order to reconsider the drug.